Carvykti's clinical findings for early lines of multiple myeloma in the CARTITUDE-2 study (cohorts A and B) reaffirm the drug's potential (Abstract # 8029, and 8020) For More Information- https://www.delveinsight.com/asco-conference/article/cartitude-2-trial?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage

1. Closely watched Janssen and Legend Biotech's CAR-T cell
therapy demonstrated durable responses in the earlier setting
of Multiple Myeloma: Updated findings from the CARTITUDE-2
trial
Updated findings from the CARTITUDE-2 trial
Carvykti's clinical findings for early lines of multiple myeloma in the CARTITUDE-2 study
(cohorts A and B) reaffirm the drug's potential (Abstract # 8029, and 8020)
Carvykti (ciltacabtagene autoleucel, Cilta-cel) is a newly approved CAR-T cell therapy for
adults with relapsed or refractory multiple myeloma (FDA approved in February 2022).
The findings of the CARTITUDE-2 trial were presented at the 2022 American Society of
Clinical Oncology (ASCO) Annual Meeting. The multicohort phase II study (NCT04133636)
evaluates the safety and efficacy of Cilta-cel in different myeloma settings, including early
lines. Patients in Cohort A include advanced multiple myeloma following 1-3 prior lines of
treatment and were lenalidomide-refractory. In contrast, patients in Cohort B had an

2. early relapse after the first therapy that included a proteasome inhibitor and an
immunomodulatory medication.
COHORT A-Data (1–3 prior lines of therapy)
At a median follow-up of 17.1 months, Cilta-Cel produced an overall response rate (ORR)
of 95%, with 90% reaching a complete response (CR) or better and 95% achieving a very
good partial response (VGPR) or better. The median time to first response was one month,
while the median time to best response was 2.6 months. The progression-free survival
(PFS) rate after 15 months was 70%. MRD negativity was reached in all 16 patients who
were MRD-evaluable at 10-5.
Cohort B Data (patients with early relapse after initial therapy): Abstract #8029
At a median follow-up of 13 months, 19 patients in this cohort had an ORR of 100%, with
90% achieving a CR or higher and 95% achieving a VGPR or better. The median response
time was one month, and the median response time was 5.1 months. The PFS rate during
12 months was 90%. 14 of the 15 MRD-evaluable patients attained MRD negative at 10-
5.
The overall safety profile of CARTITUDE-2 cohorts, including the incidence of Cytokine
Release Syndrome (CRS) and the most prevalent hematologic adverse events (AEs), was
comparable with that of CARTITUDE-1.
“We have lots of clinical trials, looking at both the approved CARTs in the earlier line
setting, including frontline and then other innovative CAR T strategies. –Expert Opinion
“The follow-up results from the ongoing CARTITUDE-2 Cohort A and B studies support the
potential of cilta-cel as a therapeutic option for earlier lines of treatment.” –Expert
Opinion.
Conclusion
There have been tremendous breakthroughs in treating multiple myeloma over the
previous decade, with the US FDA approving a wide range of treatments. The most recent
evidence for bispecific antibodies, not just BCMA, but also other novel markers, such as
GPRC5D (G-protein coupled receptor family C group 5 member D), to BCMA-CAR-T Cell
therapies, have shown encouraging outcomes in a severely pretreated multiple myeloma
patient pool. Many drugs have demonstrated their efficacy in the later-line setting, which
is why the emphasis has shifted to earlier lines. Likewise, CAR-T Cell therapies are broadly
accepted in the relapsed/refractory patient pool (Abecma and Carvykti have been FDA
approved for patients with multiple myeloma who have received four prior lines of

3. therapies), but companies are attempting to broaden their prescription and leverage on
the early lines of settings. Cilta-Cel has demonstrated early, substantial, and long-lasting
responses in heavily pretreated patients with Multiple Myeloma, leading to United States
Food and Drug Administration (FDA) approval. Although Janssen and Legend biotech
primarily targeted the later line of multiple myeloma, the CARTITUDE-2 trial ASCO result
suggests that CAR-T cell therapy could be offered in early lines. Aside from the
CARTITUDE-2 trial [NCT04133636], multiple myeloma therapy companies, J&J and Legend
are undertaking extensive research on Cilta-Cel in early-line settings (CARTITUDE-4
[NCT04181827] and CARTITUDE-5 [NCT04923893]) and outpatient settings.
Companies- Oncopeptides, GlaxoSmithKline, Bluebird Bio, Janssen Pharmaceutical,
Legend Biotech, AbbVie, Roche (Genentech), Bristol Myers Squibb, Regeneron
Pharmaceuticals, Pfizer, Takeda, Amgen, SpringWorks Therapeutics, Adicet Bio, Arcellx,
Gracell Biotechnologies, Oricell, Poseida Therapeutics, Precision Biosciences, CRISPR
Therapeutics AG, Collectis SA, Allogene Therapeutics, Fortis Therapeutics, Novartis, I-
Mab/MorphoSys, Cartesian Therapeutics, CASI Pharmaceuticals, LAVA Therapeutics, and
others.
Latest Pharmaceuticals Market Research Reports 2022 by DelveInsight
1. Medical Marijuana Market
2. NPC Market
3. Tourette Syndrome Market
4. Oncolytic Virus Cancer Therapy Pipeline
5. Myeloproliferative Neoplasms Market
6. Shigellosis Market
7. CAR-T Pipeline
8. Urology Ultrasounds Devices Market
9. Myopia Treatment Devices Market
10.Alkaptonuria Market
11.Atopic Dermatitis AD Market
12.Axillary Hyperhidrosis Market
13.Fabry Disease Market
14.Rubella Market
15.Post-Transplant Lymphoproliferative Disorder Market
16.Coccidioidomycosis Market
17.Focal Segmental Glomerulosclerosis Market
18.Pigment Epithelial Detachment Market
19.Farber’s Disease Market

4. 20.Advanced Liver Cancer Market
21.Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome Market
22.Opioid-related Disorders Market
23.Myopia Progression Market Share
24.Chronic Venous Ulceration Market
25.Ptosis Market
26.Human Papillomavirus-positive Oropharyngeal Cancer Market
27.Trauma Fixation Devices Market
28.Eosinophilic Disorder Market
29.Epidemic Parotitis Market
30.Cystinuria Market
31.Familial Lipoprotein Lipase Deficiency Market